AR099428A1 - COMBINATIONS OF PHARMACEUTICAL ACTIVE PRINCIPLES WITH TRI-BASED COMPUTERS (IET) ARIL PIRAZOLES - Google Patents
COMBINATIONS OF PHARMACEUTICAL ACTIVE PRINCIPLES WITH TRI-BASED COMPUTERS (IET) ARIL PIRAZOLESInfo
- Publication number
- AR099428A1 AR099428A1 ARP150100443A ARP150100443A AR099428A1 AR 099428 A1 AR099428 A1 AR 099428A1 AR P150100443 A ARP150100443 A AR P150100443A AR P150100443 A ARP150100443 A AR P150100443A AR 099428 A1 AR099428 A1 AR 099428A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- solvates
- combinations
- pirazoles
- aril
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un principio farmacéutico activo desde el punto de vista antiviral a) de acuerdo con el compuesto según la fórmula (1), en donde X se refiere a N o CH y R¹ se refiere a un sustituyente halógeno y R² se refiere a H o CH₃, o una de sus sales aceptables desde el punto de vista fisiológico, los solvatos o uno de los solvatos de sus sales, para usar en la prevención o el tratamiento de infecciones virales, y enfermedades causadas por ellos en un individuo, donde el uso del principio farmacéutico activo desde el punto de vista antiviral a) se combina con el uso de al menos un principio farmacéutico activo desde el punto de vista antiviral b) que es diferente de a), que se seleccionará de un grupo que abarca inhibidores nucleósidos y nucleótidos de la transcriptasa inversa, los inhibidores no nucleósidos de la transcriptasa inversa, los inhibidores de proteasa, los inhibidores de entrada e inhibidores de integrasa así como también combinaciones de los anteriores y sus las sales aceptables desde el punto de vista fisiológico, los solvatos o los solvatos de sus sales.Claim 1: An antiviral active pharmaceutical principle a) according to the compound according to formula (1), wherein X refers to N or CH and R¹ refers to a halogen substituent and R² refers to H or CH₃, or one of its physiologically acceptable salts, solvates or one of the solvates of its salts, for use in the prevention or treatment of viral infections, and diseases caused by them in an individual, where the Use of the antiviral active pharmaceutical principle a) is combined with the use of at least one antiviral active pharmaceutical principle b) that is different from a), which will be selected from a group comprising nucleoside inhibitors and nucleotides of reverse transcriptase, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors and integrase inhibitors as well as combinations of the ante riors and their physiologically acceptable salts, solvates or solvates of their salts.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14155296 | 2014-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099428A1 true AR099428A1 (en) | 2016-07-20 |
Family
ID=50073116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100443A AR099428A1 (en) | 2014-02-14 | 2015-02-13 | COMBINATIONS OF PHARMACEUTICAL ACTIVE PRINCIPLES WITH TRI-BASED COMPUTERS (IET) ARIL PIRAZOLES |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR099428A1 (en) |
| WO (1) | WO2015121413A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012016908A1 (en) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris (hetero) aryl-pyrazoles and their use |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| SG11201804037XA (en) * | 2015-11-16 | 2018-06-28 | Evonik Roehm Gmbh | Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) |
| WO2021062546A1 (en) * | 2019-10-01 | 2021-04-08 | Taimed Biologics Inc. | Use of ibalizumab for the treatment of hiv-2 infection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008015032A1 (en) * | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituted pyrazolamides and their use |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| EP2595986A2 (en) * | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| EP2632461A4 (en) * | 2010-10-29 | 2014-04-02 | Merck Sharp & Dohme | Isoindolinone pde10 inhibitors |
| DE102012016908A1 (en) * | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris (hetero) aryl-pyrazoles and their use |
-
2015
- 2015-02-13 AR ARP150100443A patent/AR099428A1/en unknown
- 2015-02-13 WO PCT/EP2015/053091 patent/WO2015121413A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015121413A1 (en) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800023A (en) | BETA-AMINO ACID ESTER PHOSPHODIAMIDE ANTIVIRAL COMPOUNDS | |
| UY37710A (en) | INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
| UY36648A (en) | INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| UY36649A (en) | INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
| ECSP17039611A (en) | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | |
| UY36212A (en) | TOLL TYPE RECEIVER MODULATORS FOR HIV TREATMENT | |
| ECSP16085206A (en) | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INIHBIDORS | |
| NI201500048A (en) | DERIVATIVES OF 5-PHENOXY-3H-PYRIMIDIN-4-ONA AND THEIR USE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | |
| CL2020000487A1 (en) | Antiviral agents against hepatitis b. | |
| NI201800058A (en) | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USED IN THE TREATMENT OF CANCER. | |
| CL2014001599A1 (en) | Compounds derived from nucleosides substituted in 4’-azido, 3’-fluoro or their salts, as inhibitors of vhc rna replication; pharmaceutical composition that includes them; and its use for the treatment or prophylaxis of hepatitis C virus (vhc) infection. | |
| UY35362A (en) | THERAPEUTIC COMPOUNDS | |
| CL2016001973A1 (en) | Nucleoside derivatives substituted with 4'-difluoromethyl as inhibitors of influenza arn replication. | |
| AR102981A1 (en) | INHIBITORS OF CELL NECROSIS AND METHODS OF PREPARATION OF THE SAME | |
| UY33885A (en) | INHIBITION OF IL17 AND IFN-GAMMA FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATIONS | |
| CO2017009994A2 (en) | New compounds and derivatives of sulfonimidoylpurinone for the treatment and prophylaxis of viral infections | |
| DOP2014000081A (en) | COMPOUNDS AND PROCEDURES TO IMPROVE INNATE IMMUNE RESPONSES | |
| CU24519B1 (en) | AMINOTIZOLE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | |
| NI201200146A (en) | NON-NUCLEOSIDIC INHIBITORS OF REVERSE TRANSCRIPTASE | |
| DOP2021000062A (en) | HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS. | |
| UY35274A (en) | COMPOUNDS AND METHODS TO TREAT BACTERIAL INFECTIONS | |
| CR20180091A (en) | 5- (N-BENCIL-TETRAHYDROISOQUINOLIN-6-IL) -PIRIDIN-3-IL ACETIC AS INHIBITORS OF HIV REPLICATION | |
| AR099428A1 (en) | COMBINATIONS OF PHARMACEUTICAL ACTIVE PRINCIPLES WITH TRI-BASED COMPUTERS (IET) ARIL PIRAZOLES | |
| DOP2016000297A (en) | PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES | |
| CL2021000329A1 (en) | Useful compounds in hiv therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |